RV.Net Open Roads Forum: Around the Campfire: 2019–20 CORONAVIRUS PANDEMIC POSTINGS

RV Blog

  |  

RV Sales

  |  

Campgrounds

  |  

RV Parks

  |  

RV Club

  |  

RV Buyers Guide

  |  

Roadside Assistance

  |  

Extended Service Plan

  |  

RV Travel Assistance

  |  

RV Credit Card

  |  

RV Loans

Open Roads Forum Already a member? Login here.   If not, Register Today!  |  Help

Newest  |  Active  |  Popular  |  RVing FAQ Forum Rules  |  Forum Posting Help and Support  |  Contact  

Search:   Advanced Search

Search only in Around the Campfire

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–20 CORONAVIRUS PANDEMIC POSTINGS

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 111  
Prev  |  Next
Sponsored By:
BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 01/18/21 07:31am Link  |  Quote  |  Print  |  Notify Moderator

New vaccine candidate being developed in association with Novartis.
Single dose
Vaccine does not need to be stored frozen and is stable at room temp for at least 1 month!

Quote:

An AAV-based, room-temperature stable, single dose COVID-19 vaccine


The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at global scale will depend on the biological and logistical attributes of the vaccine. Here, two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and nonhuman primates following a single injection. Peak neutralizing antibody titers remain sustained at 5 months and are complemented by functional memory T-cells responses. The AAVrh32.33 capsid of the AAVCOVID vaccine is an engineered AAV to which no relevant pre-existing immunity exists in humans. Moreover, the vaccine is stable at room temperature for at least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry. Thus, this methodology holds as a very promising single dose, thermostable vaccine platform well-suited to address emerging pathogens on a global scale.


BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 01/18/21 07:46am Link  |  Quote  |  Print  |  Notify Moderator

Phase 1/2 trial results for the J&J vaccine
four different dosing regimens are being evaluated:
1 low dose
2 low doses
1 high dose
2 high doses



Quote:

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine


Background

Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.

Methods

In this multicenter, placebo-controlled, phase 1–2a trial, we randomly assigned healthy adults between the ages of 18 and 55 years (cohort 1) and those 65 years of age or older (cohort 3) to receive the Ad26.COV2.S vaccine at a dose of 5×1010 viral particles (low dose) or 1×1011 viral particles (high dose) per milliliter or placebo in a single-dose or two-dose schedule. Longer-term data comparing a single-dose regimen with a two-dose regimen are being collected in cohort 2; those results are not reported here. The primary end points were the safety and reactogenicity of each dose schedule.

Results

After the administration of the first vaccine dose in 805 participants in cohorts 1 and 3 and after the second dose in cohort 1, the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in those who received the high dose. Reactogenicity was lower after the second dose. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose (geometric mean titer GMT, 224 to 354) and reached 100% by day 57 with a further increase in titers (GMT, 288 to 488), regardless of vaccine dose or age group. Titers remained stable until at least day 71. A second dose provided an increase in the titer by a factor of 2.6 to 2.9 (GMT, 827 to 1266). Spike-binding antibody responses were similar to neutralizing-antibody responses. On day 14, CD4+ T-cell responses were detected in 76 to 83% of the participants in cohort 1 and in 60 to 67% of those in cohort 3, with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses were robust overall but lower in cohort 3.

Conclusions

The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276. opens in new tab.)


BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 01/18/21 10:45am Link  |  Quote  |  Print  |  Notify Moderator

This is a good article
Vaccines Need Not Completely Stop COVID Transmission to Curb the Pandemic

qtla9111

Monterrey, Mexico

Senior Member

Joined: 09/17/2003

View Profile


Offline
Posted: 01/18/21 12:12pm Link  |  Quote  |  Print  |  Notify Moderator

Is there a chart (or has it been posted) that shows the different vaccines and their efficacy rate? Mexico is now going with the Sputnik V which has a lower efficacy rate than others.

https://medicalxpress.com/news/2021-01-mexico-russia-sputnik-vaccine.html

Mexico has also been asked by the United Nations to delay the Pfizer purchase in order to get more doses to poorer countries quicker.

Mexico says it's OK with getting less Pfizer vaccine for now


2005 Dodge Durango Hemi
2008 Funfinder 230DS
Living and Boondocking Mexico Blog

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 01/19/21 08:02am Link  |  Quote  |  Print  |  Notify Moderator

Here is another good overview article
3 Questions And The Emerging Answers About COVID-19 Vaccine Protection

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 01/19/21 08:09am Link  |  Quote  |  Print  |  Notify Moderator

This study found that viral loads increase with age and not that children have higher viral loads.

Quote:

SARS-CoV-2 viral load distribution in di........eals that viral loads increase with age.

Objectives: To describe the SARS-CoV-2 viral load distribution in different patient groups and age categories. Methods: All SARS-CoV-2 RT-PCR results from nasopharyngeal (NP) and oropharyngeal (OP) swabs (first PCR from unique patients only) that were collected between January 1 and December 1, 2020, in the Public Health Services regions Kennemerland and Hollands Noorden, province of Northern Holland, the Netherlands were included in this study. Swabs were derived from patients with respiratory symptoms who were presented at the general practitioner (GP) or hospital, hospital health care workers (HCWs) of four regional hospitals, nursing home residents and HCWs of multiple nursing homes, and in majority (>75%) from Public Health testing facilities of the two Public Health Services. SARS-CoV-2 PCR crossing point (Cp) values were used to estimate viral loads (higher Cp-values indicate lower viral loads). Results: In total, 278.470 unique patients were tested of whom 9.1% (n=25.365) were SARS-CoV-2 positive. As there were differences in viral load distribution between tested populations, further analyses focused on PCRs performed by public health services (n=211.933) where sampling and inclusion were uniform. These data present reveal a clear relation between age and SARS-CoV-2 viral load, with especially children aged79 years) and youngest (30 was significantly higher compared to the other patients (31.1% vs. 16.9%, p-value<0.001). Conclusion: We observed that in patients tested by public health services, SARS-CoV2 viral load increases significantly with age. Previous studies suggest that young children (<12 years) play a limited role in SARS-CoV-2 transmission. Currently, the relation between viral load and infectivity is not yet well understood, and further studies should elucidate whether the lower viral load in children is indeed related to their suggested limited role in SARS-CoV-2 transmission. Moreover, as antigen tests are less sensitive than PCR, these results suggest that SARS-CoV-2 antigen tests could have lower sensitivity in children than in adults.


silversand

Montreal

Senior Member

Joined: 09/12/2004

View Profile



Posted: 01/19/21 01:28pm Link  |  Quote  |  Print  |  Notify Moderator

....on the Brazil front, we all know about the new more virulent sub-type that has escaped Brazil, and is now infecting people in North America. Brazil has started their vaccination campaign on 17th January.

China had shipped 6 million doses of Sinovac (efficacy: 50.38% it barely makes the WHO vaccine efficacy threshold) to Brazil for deployment into arms on the 17th. Both Sinovac and AstraZeneca have been approved in Brazil by ANVISA on Jan 17th.

So what of AstraZeneca in Latin America? The Instituto Butantan is manufacturing AstraZeneca in Brazil, and the roll-out of this vaccine is supposed to start in Brazil in days.

(site: John Campbell PhD SitRep here-->


Silver
2004 Chevy Silverado 2500HD 4x4 6.0L Ext/LB Tow Package 4L80E Michelin AT2s| Outfitter Caribou

BradW

Mayor of Flat Rock

Senior Member

Joined: 10/29/2001

View Profile



Posted: 01/19/21 03:27pm Link  |  Quote  |  Print  |  Notify Moderator

I get vaccinated in about 3 hours.

* This post was edited 01/20/21 05:35am by BradW *


Wake Up America
2019 Lance 1062 and 2018 F-350 CC PSD 4X4 DRW
Tembrens, Rear Roadmaster Sway Bar, Torklift 48" Extention and 30K Superhitch
Our New Lance 1062 Truck Camper Unloading at Dealer Photos


silversand

Montreal

Senior Member

Joined: 09/12/2004

View Profile



Posted: 01/20/21 08:41am Link  |  Quote  |  Print  |  Notify Moderator

Brad:

Let us know how the 1st jab works out!

silversand

Montreal

Senior Member

Joined: 09/12/2004

View Profile



Posted: 01/20/21 08:54am Link  |  Quote  |  Print  |  Notify Moderator

....this is quite interesting:

Jan 14th 2021; Public Health England (PHE) SIREN;

"PHE scientists working on the study have concluded naturally acquired immunity as a result of past infections provide 83% protection against reinfection, compared to people who have not had the disease before. This appears to last at least for 5 months from first becoming sick."

"While the SIREN study will continue to assess whether protection may last for longer, this means people who contracted the disease in the first wave may now be vulnerable to catching it again."

"PHE also warned that although those with antibodies have some protection from becoming ill with COVID-19 themselves, early evidence from the next stage of the study suggests that some of these individuals carry high levels of virus and could continue to transmit the virus to others."

here-->

My read of this is: ...even if you have had Covid, it makes sense to get the full course of vaccine following the vaccine manufacturer's wait period.

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 111  
Prev  |  Next

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–20 CORONAVIRUS PANDEMIC POSTINGS
Search:   Advanced Search

Search only in Around the Campfire


New posts No new posts
Closed, new posts Closed, no new posts
Moved, new posts Moved, no new posts

Adjust text size:




© 2021 CWI, Inc. © 2021 Good Sam Enterprises, LLC. All Rights Reserved.